Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE

Biocon's share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company's seventh USFDA-approved biosimilar and enhances its oncology portfolio, increasing investor confidence and market optimism.

Markets